Regeneron | pharmaphorum

Tuesday 26 November 2024

Channels

Content type

Categories

Categories

Sort by

Order

Regeneron

News

French pharma company Sanofi

FDA approves Sanofi/Regeneron's Dupixent in asthma

The US regulator has approved Sanofi/Regeneron’s Dupixent (dupilumab) in a new asthma indication, a key step in the companies attempt to build a blockbuster franchise around the drug.

News

Sanofi/Regeneron's Dupixent could be first biologic approved for nasal polyps

Sanofi/Regeneron's Dupixent could be first biologic approved...

Trials of Sanofi and Regeneron’s drug Dupixent (dupilumab) have shown positive results for treating patients suffering from chronic rhinosinusitis with nasal polyps, teeing up a potential n

News

regeneron

Regeneron/Teva pain drug fasinumab on target in phase 3

Pfizer and Eli Lilly are competitors in NGF research

News

cancer-t-cells-16_9

Regeneron forges CAR-T R&D partnership with bluebird bio

Deal combines Regeneron's receptor tech with CAR-T biotech's expertise

News

Amgen Repatha evolocumab

Amgen's Repatha gets EU cardio risk reduction label

But Sanofi/Regeneron could have advantage thanks to price cut and better data

News

The liver is a vital organ of the digestive system present in vertebrates and some other animals. It has a wide range of functions, including detoxification, protein synthesis, and production of biochemicals necessary for digestion.

Regeneron and Alnylam seek RNAi therapies for NASH

Regeneron and Alnylam are to research treatments for the chronic liver disease non-alcoholic steatohepatitis (NASH), under a new agreement.